Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tilvestamab in Platinum-Resistant High-Grade Serous Ovarian Cancer
NCT04893551Phase 1Terminated
- Sponsor
- BerGenBio ASA
- Start
- Feb 2021
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of tilvestamab in High-Grade Serous Ovarian Carcinoma (HGSOC), sponsored by BerGenBio ASA. Primary endpoints: Number of Participants with Adverse events (AEs) and Serious AEs (SAEs) up to 2.5 years, Number of Participants with Laboratory Abnormalities up to 2.5 years and 3 more. Started Feb 2021; status: terminated.
02
Drugs
tilvestamab
03
Conditions
High-Grade Serous Ovarian Carcinoma (HGSOC)
Beyond the preview
Go deeper on NCT04893551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04893551.